Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

How many patients get up and walk out

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Monroe1 Member Profile
 
Followed By 188
Posts 25,086
Boards Moderated 2
Alias Born 05/30/12
160x600 placeholder
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
CytoDyn’s leronlimab reduces mortality by 82% at 14 days in critically ill COVID-19 patients Seeking Alpha - 3/30/2021 7:08:56 AM
Philippines OKs use of CytoDyn's leronlimab in COVID-19 Seeking Alpha - 3/29/2021 6:30:52 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/18/2021 7:46:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 8:31:13 AM
CytoDyn promotes from within for COO role Seeking Alpha - 3/16/2021 6:03:45 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, The Next Short Squeeze InvestorsHub NewsWire - 3/11/2021 7:53:20 AM
Enrollment underway in CytoDyn’s long-haulers COVID-19 trial Seeking Alpha - 3/11/2021 5:49:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 5:28:38 PM
CytoDyn to release CD12 trial data on March 8 Seeking Alpha - 3/8/2021 6:34:51 AM
CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada Seeking Alpha - 3/7/2021 11:56:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2021 8:32:38 AM
Monroe1   Tuesday, 05/04/21 05:23:45 PM
Re: None
Post # of 164279 
How many patients get up and walk out of the hospital within a few days when taking this junk that long term effects are unknown?
https://www.physiciansweekly.com/conflicting-data-on-remdesivir-for-covid-19-highlight-efficacy-questions/

https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/table--remdesivir-clinical-data/
Table 2a. Remdesivir: Selected Clinical Data

Last Updated: February 11, 2021

The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for RDV. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.


* If leronlimab was owned by a a BP company it would have been on the market before ramitsevir was EUA'd.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences